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Background
The B cell receptor (BCR) expressed by a clonal B cell
tumor is a tumor specific antigen (idiotype). However,
the T cell epitopes within human BCRs which stimulate
protective immunity still lack detailed characterization.
Methods
In this study, we identified 17 potential CD4 T cell peptide
epitopes derived from BCR heavy and light chain variable
region sequences. Detailed analysis revealed these CD4
T cell epitopes stimulated Th1 CD4 T cells to directly
recognize the autologous tumors by secretion of IFN-g,
indicating the epitopes are processed and presented by
tumors.
Results
One BCR peptide-specific CD4 T cell line was also cyto-
toxic and lysed autologous tumor cells through the per-
forin pathway. Sequence analysis of the epitopes revealed
10 were potentially shared by multiple primary patients’
tumors, and 16 had the capacity to bind more than one
HLA DRB1 allele. T cells stimulated by shared epitopes
recognized primary tumors expressing the same sequences
on different HLA DRB1 alleles.
Conclusions
In conclusion, we identified multiple BCR-derived CD4
T cell epitopes with promiscuous HLA binding that are
shared by up to 36% of patients, suggesting a strategy to
overcome the requirement for individual preparation of
therapeutic agents targeting idiotype.
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